Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs TransMedics Group Inc — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $74.1, while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SPLV | TMDX | |
|---|---|---|
52-Week High | $77.97 | $150.42 |
52-Week Low | $70.30 | $61.99 |
Market Cap | — | $3.06B |
Sector | — | Technology |
Enterprise Value | — | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV, the Invesco S&P 500 Low Volatility ETF, trades at $74.55, down 0.25% on the day, with a bearish technical signal driven by moving averages. The ETF has underperformed the S&P 500, returning 5% versus 17%, due to sector overweights in Utilities, Real Estate, and Financials. Recent news highlights its role as a stability-focused option amid market volatility, with dividends scheduled for mid-2026.
The outlook for SPLV is neutral to cautious, offering defensive exposure but facing headwinds from unappealing growth-adjusted valuations and sector concentration risks. Investment appeal hinges on market volatility trends, while risks include prolonged underperformance if low-volatility sectors lag in a growth-oriented market.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
